Losartan for Patients With COVID-19 Not Requiring Hospitalization

Summary

This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).

Timeline

Start

2020-04-09

Primary completion

2021-02-01

Completion

2021-02-01

Outcome

Missed primary endpoint

paper The primary outcome did not differ significantly between the two arms based on Barnard's test PMID 34195577 ↗

paper Interpretation: In this multicenter blinded RCT for outpatients with mild symptomatic COVID-19 disease, losartan did not reduce hospitalizations PMID 34195577 ↗

Publications

• Results Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Reilkoff RA, Driver BE, Biros MH, Bellolio F, Chipman JG, Nelson AC, Beckman K, Langlois R, Bold T, Aliota MT, Schacker TW, Voelker HT, Murray TA, Koopmeiners JS, Tignanelli CJ. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine. 2021 Jun 17;37:100957. doi: 10.1016/j.eclinm.2021.100957. eCollection 2021 Jul.
• Smolander J, Bruchfeld A. [COVID-19 and kidney disease]. Lakartidningen. 2020 Jul 13;117:20110. Swedish.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Losartan	Other / unclassified	25 mg	Oral

Indications